The iC-GN Assay detects target DNA and identifies gram-negative organisms associated with gram-negative bacteremia, and three antibiotic-resistance markers.
The firm's CEO said it is continuing to develop its distributor network to make its tests available in centralized and decentralized settings globally.
Roche said that the test aids clinicians in accelerating tuberculosis diagnosis and treatment by detecting resistance to the antibiotics rifampicin and isoniazid.
The PCR-based test is designed to detect 47 antibiotic resistance genes in less than three hours from bacterial isolates to help guide treatment decisions.
ArcDia will provide Xinhua its biochemical assay components and R&D services in order to localize the Finnish firm's MariPOC testing platform in China.
CEO Yoel Ezra said the firm plans to deploy a prototype in pilot studies next year, and is eyeing opportunities in the US, Europe, India, and the Middle East.
